Expanding the scope of noninvasive prenatal testing: detection of fetal microdeletion syndromes  by Wapner, Ronald J. et al.
Research ajog.org
OBSTETRICSExpanding the scope of noninvasive
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Matthew Rabinowitz, PhD; Susan J. Gross, MD; Matthew Hill, PhD; Peter Benn, DScOBJECTIVE: The purpose of this study was to estimate the perfor- deletion (1/1), and cri-du-chat syndromes (24/24). False-positive
mance of a single-nucleotide polymorphism (SNP)ebased noninvasive
prenatal test for 5 microdeletion syndromes.
STUDY DESIGN: Four hundred sixty-nine samples (358 plasma
samples from pregnant women, 111 artificial plasma mixtures) were
amplified with the use of a massively multiplexed polymerase chain
reaction, sequenced, and analyzed with the use of the Next-generation
Aneuploidy Test Using SNPs algorithm for the presence or absence of
deletions of 22q11.2, 1p36, distal 5p, and the Prader-Willi/Angelman
region.
RESULTS: Detection rates were 97.8% for a 22q11.2 deletion (45/
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332.e1 American Journal of Obstetrics& Gynecology MARCH 2015rates were 0.76% for 22q11.2 deletion syndrome (3/397) and
0.24% for cri-du-chat syndrome (1/419). No false positives
occurred for Prader-Willi (0/428), Angelman (0/442), or 1p36
deletion syndromes (0/422).
CONCLUSION: SNP-based noninvasive prenatal microdeletion screen-
ing is highly accurate. Because clinically relevant microdeletions
and duplications occur in>1% of pregnancies, regardless of maternal
age, noninvasive screening for the general pregnant population should
be considered.
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revolution in prenatal screening.1-3
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high sensitivity and speciﬁcity4 and havefacilitated a signiﬁcant reduction in the
number of invasive diagnostic pro-
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TABLE 1
Samples used in the main cohort along with the sample deletion sizes
Samples Sample deletion size n
Pregnancy samples
DiGeorge deletion arr[hg18] 22q11.21(17,010,000-20,130,000)x1 1
DiGeorge deletion arr[hg18] 22q11.21(17,020,000-20,130,000)x1 1
DiGeorge deletion 46,XX.nuc ish(HIRAx1) 1
Cri-du-chat deletion 46,XX,del(5)(p15.1p15.3) 1
Cri-du-chat deletion 46,XY,del(5)(p14.2) 1
1p36 deletion 46,XY,del(1)(p36.1) 1
46,XX and 46,XY 352
PlasmArt samples: born triads
DiGeorge deletion arr[hg18] 22q11.2(17,270,000- 19,810,000)x1 22
DiGeorge deletion arr[hg18] 22q11.2(16,950,000-20,250,000)x1 22
Cri-du-chat deletion arr[hg18] 5p15.33p14.1(91,100-29,500,000)x1 22
46,XX and 46,XY 7
PlasmArt samples: cell lines
Prader-Willi deletion arr[hg18] 15q11.2q13.1(20,310,000-27,130,000)x1 16
Angelman deletion arr[hg18] 15q11.2q13.1(20,310,000-27,220,000)x1 22
Wapner. Noninvasive screening for fetal microdeletion syndromes. Am J Obstet Gynecol 2015.
FIGURE 1
Fetal fraction distribution
Distribution of the 111 PlasmArt samples and of 19,910 consecutive commercial samples from
10-16 weeks’ gestation.
Wapner. Noninvasive screening for fetal microdeletion syndromes. Am J Obstet Gynecol 2015.
ajog.org Obstetrics Researchchromosome abnormalities. The SNP-
based approach is also able to detect
triploidy.9,11
Subchromosomal abnormalities
(microdeletions and duplications) may
result in physical and/or intellectual
impairments that can be more severe
than whole chromosome abnormalities.
Unlike the risks of aneuploidy that is
associated with nondisjunction, the
incidence of subchromosomal copy
number variations (CNVs) is indepen-
dent of maternal age. Clinically relevant
microdeletions and duplications occur
in 1-1.7% of all structurally normal
pregnancies.14 In younger women, the
risk for a clinically signiﬁcant deletion
exceeds the risk for Down syndrome.
Because some infants with sub-
chromosomal abnormalities may
beneﬁt from early therapeutic inter-
vention,15-17 prenatal detection is
important for optimal management. In
support of this, it is recommended that
chromosome microarray analysis be
offered to all women who undergo
invasive diagnostic testing.18 However,
with the introduction of NIPT for
aneuploidy screening, many women
who previously would have had invasive
testing are choosing to avoid these
procedures because of the small risk of
pregnancy loss.3,19
Submicroscopic genomic alterations
are harder to detect noninvasively
because of their small size. A small
proportion may be identiﬁed inciden-
tally through traditional serum and
ultrasound screening, but these tests
were not designed to screen for these
anomalies. The introduction of a
highly accurate noninvasive prenatal
screening test that would identify
women who are at high risk for
microdeletions or duplications there-
fore would be useful. Recently, proof-
of-principle studies that used shot-
gun or whole-genome sequencing
reported the detection of sub-
chromosomal microdeletions and
microduplications.20-23 However, these
approaches were limited by the
requirement for exceptionally high
sequence reads, and interpretation
was complicated by the identiﬁcation
of variants of unknown clinicalsigniﬁcance. Here, we used a targeted
SNP-based approach9-13 to detect the
larger deletions that underlie 5 mi-
crodeletion syndromes with clinically
severe phenotypes.MARCH 2015 AmeriMATERIALS AND METHODS
Initial validation studies were performed
with genomic DNA that had been iso-
lated from 40 characterized cell lines to
demonstrate that the SNP-targeted assaycan Journal of Obstetrics& Gynecology 332.e2
FIGURE 2
Graphic representation of sequencing data
Data were obtained from analysis of genomic DNA isolated from cells with the 22q11.2 deletion,
interrogated for A, the 1p36 deletion, B, the cri-du-chat deletion, C, the Prader-Willi/Angelman
deletion, and D, the 22q11.2 deletion. Note that this is one way of visualizing the data and is not
how the algorithm makes copy number calls. For all plots, single-nucleotide polymorphisms (SNPs)
are assumed to be dimorphic and are labeled as A or B. The fraction of A allele reads (y-axis) is
plotted against the position of each SNP along the chromosome of interest (x-axis); each spot
corresponds to a single SNP. Spots are colored according to genotype: AA is red; AB is green, and BB
is blue. Genotypes are indicated to the right of the plots; A-C, SNP plots reveal 2 copies in the 1p36,
cri-du-chat, and Prader-Willi/Angelman regions. Homozygous alleles (AA and BB) are associated
tightly with the plot’s upper and lower limits, respectively. Heterozygous alleles (AB) cluster near the
center of the plot, which indicates 2 copies of the chromosome in the interrogated regions. D, SNP
plots reveal 1 copy in the 22q11.2 region. The lack of heterozygous alleles (AB) identifies 1 copy of
the 22q11.2 region; A and B alleles are associated tightly with the plot’s upper and lower limits,
respectively.
Wapner. Noninvasive screening for fetal microdeletion syndromes. Am J Obstet Gynecol 2015.
Research Obstetrics ajog.orgwas capable of detecting the presence or
absence of 22q11.2, 1p36, cri-du-chat,
Prader-Willi, and Angelman deletions.
These cell lines included 7 with 22q11.2
deletions, 19 with 5p deletions (cri-du-
chat syndrome), 10 with 15q11-13 de-
letions (3 with Angelman syndrome and
7 with Prader-Willi syndrome), and 4
with no deletions.
After validation of the SNP-targeted
assay, a cohort of 469 test samples was332.e3 American Journal of Obstetrics& Gynecolevaluated (Table 1). This included 6
maternal plasma samples from pregnant
women in which the fetus had a micro-
deletion (3 with 22q11.2 deletions, 2
with 5p deletions, and 1 with a 1p36
deletion), 352 unaffected pregnancy
plasmas, and 111 artiﬁcial DNA mix-
tures (PlasmArts). Seventy-three of the
PlasmArts were generated from DNA
derived from 2 individuals with 22q11.2
deletions, 1 with a 5p deletion, and oneogy MARCH 2015unaffected child, each of which was
diluted into matched maternal DNA.
Thirty-eight samples were generated
from genomic DNA isolated from two
15q-cell lines (1 Angelman, and 1
Prader-Willi) and the corresponding
maternal cell lines. All cell lines were
obtained from the Coriell Cell Re-
pository (Camden, NJ). Patients who
provided samples were enrolled at pre-
natal and postnatal care centers under
institutional review boardeapproved
protocols (Western Institutional Review
Board protocol number: 12-014-NPT),
pursuant to local regulations.
Genomic DNA for PlasmArt mixtures
was isolated from the buffy coats from
mother and child pairs or from paired
mother and child cell lines. These DNA
preparations were cleaved into inter-
nucleosomal fragments of roughly 150
base pairs and multiples thereof with the
use of a proprietary reaction that included
micrococcal nuclease (New England
Biolabs, Ipswich, MA).24,25 Because fetal
cfDNA exists in vivo mainly as mono-
nucleosomal fragments,26 child DNA of
approximately 150 base pairs was isolated
using Solid Phase Reversible Immobili-
zation beads (Agencourt Biosciences,
Beverly, MA). Maternal genomic DNA
was not size puriﬁed because maternal
cfDNA exists as a nucleosomal ladder.26
Child DNA was titrated into the corre-
sponding maternal DNA to achieve arti-
ﬁcial mixtures with “fetal” fractions that
ranged from 3.8-33%, which was a
similar distribution to that observed in
maternal plasma clinical samples. The
“fetal” fraction distribution of these
samples is shown in Figure 1; for com-
parison, the fetal fraction distribution
from 19,910 consecutivematernal plasma
samples from women at 10-16 weeks of
gestation is also shown.
All samples, including maternal and
(when available) paternal samples,9-13
underwent targeted multiplex polymer-
ase chain reaction and were sequenced;
the data were analyzed with the Next-
Generation Aneuploidy Test Using
SNPs (NATUS) algorithm as described
previously,9-13 with the following alter-
ations: a unique set of primers was
designed to amplify 4128 SNPs in the
regions-of-interest (672 SNPs targeting
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MARCH 2015 Ameri2.91 Mb in the 22q11.2 region and 1152
SNPs in each of the other regions, tar-
geting 5.85 Mb in the Prader-Willi/
Angelman region, 10.0 Mb in the 1p36
region, and 20.0 Mb in the cri-du-chat
region). The assay was not validated for
the smaller, less-frequent deletions that
are associated with these disorders
because positive control samples were
not available. The estimated relative
prevalence of the targeted deletions in
the 22q11.2, Prader-Willi/Angelman,
1p36, and cri-du-chat regions were
87%, 28%, 60%, and 65%, respectively.
Samples were analyzed with the NATUS
algorithm as previously described,9-13
and all samples that passed quality con-
trol (QC) were included in this cohort.
The NATUS algorithm was then used to
predict fetal copy number (1, 2, or 3
copies) for themicrodeletion regions-of-
interest. The algorithm was blinded to
sample status, and all calls were reported
as predicted by the algorithm without
subjective modiﬁcation by laboratory
personnel.
RESULTS
Algorithm validation using genomic
samples
Validation experiments conﬁrmed that
the SNP-based technology and the
microdeletion-speciﬁc primer pools
could detect the microdeletions accu-
rately in the 5 syndromes described.
Heterozygous SNPs clearly were absent
in all affected regions and were present
in all unaffected regions; Figure 2 shows
the graphic representations of the se-
quencing data that were obtained from
genomic DNA that had been isolated
from one cell line with a 22q11.2 dele-
tion. The plots are described in detail
in the legend of Figure 2. Brieﬂy, the
absence of the central green cluster in the
22q11.2 (DiGeorge) region indicated a
lack of heterozygous SNPs, fromwhich it
is possible to infer a deletion of one copy
of the DNA in this region.Pregnancy plasma cohort
Of the 358 pregnancy samples, 335
samples passed QC metrics. The algo-
rithm did not return a result for 23 of
358 of the samples (6.4%); all of thesecan Journal of Obstetrics& Gynecology 332.e4
FIGURE 3
Graphic representation of 1 cri-du-chat deletion pregnancy plasma with
33% fetal fraction
Single-nucleotide polymorphism (SNP) data are represented as described in Figure 2. In this case,
spots are colored according to maternal genotype: SNPs for which the mother is homozygous for the
A allele (AA) are indicated with red; SNPs for which the mother is homozygous for the B allele (BB) are
indicated with blue, and SNPs for which the mother is heterozygous (AB) are indicated in green.
Because plasma cell-free DNA is a mixture of fetal and maternal cell-free DNA, the vertical position of
each spot represents the sum of the contribution of both fetal and maternal allele reads and is a
function of the fetal fraction. Because most plasma cell-free DNA is maternal in origin, the spots
mainly distribute according to maternal genotype. The contribution of fetal allele reads results in
segregation into distinct subclusters. Fetal and maternal genotypes at individual SNPs are indicated
with F and M, respectively, to the right of the plots. A-C, SNP plots reveal 2 fetal copies in the 1p36,
Prader-Willi/Angelman, and 22q11.2 regions. The presence of 3 green clusters in the center of the
plot (centered on 0.335, 0.50, and 0.665), and the presence of 2 red (centered on 1 and 0.835) and
2 blue (centered on 0 and 0.165) clusters, indicate the presence of 2 fetal chromosomes in the
interrogated regions. D, SNP plots reveal 1 fetal copy of the cri-du-chat region. The center trio of
green clusters is replaced with a duo of clusters (centered on 0.4 and 0.6), and the peripheral red
and blue clusters have shifted towards the center of the plot (centered on 0.2 and 0.8, respectively).
Together, this indicates the presence of a deletion on the maternal chromosome in the cri-du-chat
region.
Wapner. Noninvasive screening for fetal microdeletion syndromes. Am J Obstet Gynecol 2015.
Research Obstetrics ajog.orgwere unaffected. The detection rates and
false-positive rates for those samples that
passed QC are listed in Table 2. Of the 6
affected pregnancy plasmas, 1 false
negative was reported (22q11.2). Of the
335 unaffected pregnancy plasmas that
passed QC, 4 false positives were332.e5 American Journal of Obstetrics& Gynecolreported (3 for the 22q11.2 deletion and
1 for the deletion associated with cri-du-
chat syndrome). Figure 3 shows a sample
with a fetal fraction of 33% having a cri-
du-chat deletion on the maternally
inherited chromosome 5. In this sample,
2 green clusters in the cri-du-chat regionogy MARCH 2015indicate a deletion; 3 green clusters in
the 1p36, Prader-Willi/Angelman, and
22q11.2 regions indicate that 2 copies of
the fetal chromosomes are present. The
patterns are described in detail in
the legend of Figure 2.
Artificial mixtures (PlasmArt)
In the cohort of 111 PlasmArt samples,
108 samples passed QC metrics. The 3
samples that did not pass (1 Angelman, 1
22q11.2 deletion, 1 Prader-Willi) were
due to low algorithm-generated conﬁ-
dence for the chromosome region of
interest (1 Angelman), no-call for
the chromosome region of interest
(1 22q11.2 deletion), or a fetal fraction
below the threshold where the algorithm
makes a high-conﬁdence copy number
call (1 Prader-Willi). The detection rates
and false-positive rates for the samples
that passed QC are presented in Table 2.
Figure 4 shows a 22q11.2 deletion on
the paternal copy of chromosome 22 that
was detected from a set of PlasmArt
samples with fetal fractions that ranged
from 25.9e4.8%. The absence of the
peripheral red and blue clusters where
the maternal genotype is homozygous
(AA or BB) is the hallmark pattern of a
deletion on the paternal copy of the
chromosome. The deletion is detectable
visually as low as 4.8% fetal fraction
(Figure 4).
COMMENT
We have demonstrated accurate detec-
tion of the 22q11.2, 1p36, cri-du-chat,
and Prader-Willi/Angelman micro-
deletions using a SNP-based NIPT
approach. Using a large cohort of unaf-
fected samples and artiﬁcial PlasmArt
mixtures that closely mimic the size
proﬁle and fetal fraction distribution of
cfDNA that is found in pregnancy
plasmas, we were able to estimate sen-
sitivities and speciﬁcities for this assay
for the microdeletion syndromes that
were studied. For evaluations carried out
at the 22q11.2 locus, in which the
number of SNPs targeted was less than
for other locations, we were able to
identify the presence of a deletion in 45
of 46 samples with the deletion and
absence in 394 of 397 unaffected samples
(Table 2). For the other 4 loci, all of
FIGURE 4
Graphic representation of PlasmArt samples
Representation with a 22q11.2 deletion on the paternal chromosome at A, 25.9% fetal fraction, B,
16.0% fetal fraction, and C, 4.8% fetal fraction. All PlasmArt samples depicted here were generated
from genomic DNA from the same mother-child pair. Three representative plots are depicted to
illustrate microdeletion detection across a wide range of fetal fractions. Single-nucleotide poly-
morphism (SNP) data are represented here as described in Figures 2 and 3. Genomic DNA that
represents the fetus and mother are indicated by F and M, respectively. Plots represent the Prader-
Willi/Angelman deletion region (as indicated with 1 above the plots) and the 22q11.2 deletion region
(as indicated with 2 above the plots). Genotypes of the Prader-Willi/Angelman region are indicated to
the left; genotypes of the 22q11.2 region are indicated to the right. The deletion on the paternal copy
of chromosome 22 in the 22q11.2 region is most clearly indicated by the red and blue peripheral
subclusters. A, At fetal fractions of above approximately 20%, the presence of 3 green subclusters in
the center of the plot (centered around 0.63, 0.50, and 0.37) with 2 red (around 1 and 0.87), and 2
blue (around 0 and 0.13) subclusters indicates the presence of 2 fetal chromosomes in the Prader-
Willi/Angelman region. By contrast, in the 22q11.2 region, the center trio of green subclusters has
condensed into a duo of clusters (centered on 0.57 and 0.43), and the internal peripheral red and
blue clusters are absent (as indicated by black boxes). Together, this indicates a single fetal
chromosome in the 22q11.2 region. B and C, At fetal fractions of less than approximately 20% in
both the Prader-Willi/Angelman and 22q11.2 regions, the center green subclusters condense to-
wards the center of the plot and become difficult to distinguish by eye. In the Prader-Willi/Angelman
regions, the internal peripheral red and blue subclusters regress towards the plots’ upper and lower
limits, respectively. In the 22q11.2 regions, the absence of the internal peripheral red and blue
subclusters in the 22q11.2 regions, which indicates a deletion on the paternal chromosome, is still
readily apparent (as indicated by black boxes), even at fetal fractions as low as 4.8%.
Wapner. Noninvasive screening for fetal microdeletion syndromes. Am J Obstet Gynecol 2015.
ajog.org Obstetrics Researchwhich targeted the same number of
polymorphic loci, deletions were detec-
ted in 61 of 61 affected samples and 1 of
1711 unaffected samples.
In clinical practice, samples that do
not return a result (no calls) for 1
microdeletions are unlikely to beredrawn because of the low previous
risk. Under the conservative assumption
that such cases would be treated as low
risk (negative), the effective detection
and false-positive rates for the 22q11.2
deletion would be 45 of 47 and 3 of 422,
respectively, and 61 of 63 and 1 of 1813,MARCH 2015 Amerirespectively, for the larger deletions
combined (Table 3). Our results suggest
that screening for this set of 5 micro-
deletions could be added to existing
NIPT for fetal aneuploidy with a mini-
mal combined incremental false-positive
rate of approximately 0.8% (Table 3).
When we combined the data for
maternal plasma samples and the Plas-
mArt samples, the detection rate for
22q11.2 deletions was 45 of 46 (97.8%),
and the false-positive rate was 3 of 397
(0.76%; Table 2). Based on a deletion
prevalence of 1 of 2000 in the general
population, an estimate that the 3-Mb
deletion constitutes 87% of all 22q11.2
deletions,27 and the conservative
assumption that this test will not identify
any of the other variant deletions, the
results would translate into a positive
predictive value of approximately 5.3%
and a negative predictive value of
approximately 99.99% (Table 4).
For the other deletion syndromes
(which, in general, constitute larger
genomic regions with more SNPs within
each region), the combined detection
rate was 61 of 61 (100%), and the false-
positive rate was 1 of 1711 (0.06%;
Table 2). These combined rates were
used to estimate positive and negative
predictive values for each disorder
(Table 4). The deletions included in this
study constitute almost 70% of the
causal mutations in the 5 syndromes.
The positive predictive value conserva-
tively assumed that none of the other
variant deletions in patients with these
disorders would be identiﬁed and also
that uniparental disomy would not be
recognized. In practice, because some of
the other deletions that are seen in these
disorders can be large and because uni-
parental disomy is expected to be
recognized, it is likely that >70% of
affected pregnancies would be found.
Further, it is possible that this assay could
detect smaller deletions. Thus, the
detection rates described here are
considered to be a conservative indica-
tion of what could be expected in a
clinical setting. To further improve the
positive predictive value, reﬂex testing of
samples found to be high risk to higher
depth of read currently is being
investigated.can Journal of Obstetrics& Gynecology 332.e6
TABLE 3
Combined detection rate and false-positive rate for pregnancy plasmas and PlasmArt samples
Variable
Effective detection ratea
Net detection rate,b %
False-positive rate
n/N 95% CI n/N % 95% CI
22q11.2 del 45/47 95.7: 85.5e99.5 83.3 3/422 0.71 0.1e2.1
Larger deletions combined 61/63 96.8: 89.0e99.6 45.5 1/1813 0.06 0.0e0.3
Samples for which the algorithm did not receive a result are treated conservatively as negatives.
CI, confidence interval.
a Detection rates for the specific detected deletions; b Net detection rates for each syndrome that take into account the prevalence of each detected deletion.
Wapner. Noninvasive screening for fetal microdeletion syndromes. Am J Obstet Gynecol 2015.
Research Obstetrics ajog.orgOur initial studies have focused on 5
microdeletion syndromes that collec-
tively have a population incidence of
approximately 1 in 1000. These disorders
are associated with signiﬁcant morbidity
and mortality rates and includes intel-
lectual disability.14,28-31 Additionally, the
SNP method that was used distinguishes
between a deletion that has arisen on a
paternally vs a maternally inherited
chromosome, which will facilitate clin-
ical interpretation when an imprinted
gene is involved, such as Prader-Willi or
Angelman syndrome, even though pa-
tients with these disorders can have
identical chromosome 15 deletions.32 It
should be recognized that, for patients
who seek comprehensive diagnostic
testing, chromosomal microarray anal-
ysis is the gold standard. However, forTABLE 4
Estimated positive predictive value a
Disorder
Incidence
(1:n)
Frequency
of deletion
evaluated
22q11.2
del
2000 0.87
Prader-
Willi
10,000 0.28
Angelman 12,000 0.28
1p36 del 5000 0.60
Cri-du-
chat
20,000 0.65
a Calculated by multiplying population incidence, the frequency
(detection rate/false-positive rate); b Calculated by multiplying p
and the negative likelihood ratio ([1-detection rate]/[1-false-po
Wapner. Noninvasive screening for fetal microdeletion synd
332.e7 American Journal of Obstetrics& Gynecolpatients who want information about
the genetic status of their fetus but who
desire to avoid invasive testing, NIPT
with broad clinical coverage can be an
appropriate ﬁrst step.
A noninvasive screening test for a
deﬁned set of submicroscopic CNVs
allows a focus on the common recur-
rent changes that are known to be
associated with well-deﬁned pheno-
types. The phenotypes associated with
CNVs in other genomic regions are
becoming increasingly well-deﬁned,
which supports their addition to a
screening approach. However, because
each CNV will be rare, it is important
that the false-positive rate for each is
very low. Our study shows that this can
be achieved while retaining a high
positive predictive value (Table 4).nd negative predictive value
Positive
predictive
value,a %
Negative
predictive
value,b %
5.3 >99.99
4.6 >99.99
3.8 >99.99
17.0 >99.99
5.3 >99.99
of the deletion evaluated, and the positive likelihood ratio
opulation incidence, the frequency of the deletion evaluated,
sitive rate]).
romes. Am J Obstet Gynecol 2015.
ogy MARCH 2015A signiﬁcant limitation of this study
was the lack of sufﬁcient maternal
plasma samples from affected pregnan-
cies at appropriate gestational ages.
Because these disorders are relatively
rare and because prenatal screening for
these disorders is unprecedented, it was
not possible to conduct a large-scale
study on patient samples. To partially
overcome this limitation, we generated
artiﬁcial pregnancy plasma mixtures,
termed PlasmArts, over an appropriate
range of fetal DNA concentrations. The
value of the PlasmArt approach is
based on a number of observations.
Plasma cfDNA is known to consist
of both maternal and fetal fragments.
The fetal fragments are mainly mono-
nucleosomal26,33 that are generated
during placental apoptosis34 and, as
such, have speciﬁc cleavage sites.
Maternal mononucleosomal fragments
are approximately 23 nucleotides longer
than fetal fragments,26,33,35,36 and
maternal cfDNA is known to consist of a
nucleosomal ladder.26 Additionally, both
the fetal and maternal DNA fragments
are thought to have associated proteins.
Thus, the enzymatic fragmentation and
“fetal”DNA size puriﬁcation used in this
study is expected to be superior to the
use of sonication,21 in that it creates
fragments similar to those observed
in vivo. Additionally, this method will
leave proteins intact, in contrast to son-
ication, which denatures proteins; how-
ever, whether this affects cfDNA-based
detection of CNVs has not been deter-
mined. Research is ongoing to further
validate the PlasmArt method as a model
for clinical samples.
ajog.org Obstetrics ResearchThe exact coordinates and size of
some CNVs will differ substantially be-
tween individuals. Because of the rarity
of positive control samples, this cohort
contained a limited number of affected
samples, including the use of replicate
PlasmArts that were derived from the
same mother-child pairs. Further vali-
dation of this technology in a larger se-
ries is warranted. Performance of this
SNP-based method for the detection of
well-deﬁned microdeletions is expected
to depend primarily on the number of
informative SNPs in each region of in-
terest. Although this may limit the
detection capabilities for small regions of
interest, for larger discrete abnormal-
ities, it should offer a robust and gener-
alizable approach. In other words,
because performance is related to the
number of informative SNPs in a target
region, and not on the identity of
the SNPs, validation of rare micro-
deletions should be possible without the
need to collect a large set of positive
controls for validation of each micro-
deletion. Ongoing studies in the clinical
population, in which more affected
samples are available, will provide
insights into the generalizability of per-
formance metrics for different micro-
deletion syndromes.
Detection of fetal microdeletions has
been reported with methods that use
shotgun sequencing and counting DNA
fragments.20,21 Because these methods
amplify all chromosomes indiscrimin-
ately and because these deletion syn-
dromes affect <1% of the genome, large
numbers of sequence reads are required
for accurate detection of sub-
chromosomal anomalies.37 In these
initial studies that used shotgun
sequencing, microdeletions were detec-
ted with the use of a depth of sequencing
between 2.4  108 and 1.3  109
sequence reads,21,38 which is substan-
tially higher than that currently used for
aneuploidy detection. The method re-
ported here achieved high sensitivity and
speciﬁcity with an average of only 8.9 
106 mapped reads, which demonstrates
one of the signiﬁcant advantages of this
targeted sequencing approach. Also,
nontargeted sequencing will identify
variants of unknown signiﬁcance,22,23which will increase the need for inva-
sive testing and can present counseling
dilemmas. Alternatively, the SNP-based
method can target speciﬁc regions with
well-described phenotypes. Although
this SNP-based approach offers a num-
ber of beneﬁts over counting methods,
there are some limitations to this
approach. The SNP method requires a
longer polymerase chain reaction pro-
cess, and, as of now, this assay is not
appropriate for egg donors.
This report describes the identiﬁca-
tion of 5 well-deﬁned microdeletion
syndromes through noninvasive
methods. This next-generation SNP-
and NATUS-based NIPT approach
routinely identiﬁed 22q11.2, 1p36, cri-
du-chat, Prader-Willi, and Angelman
microdeletions with a low rate of
screen positive results. The fact that
clinically relevant microdeletions and
duplications occur in >1% of preg-
nancies, regardless of maternal age,
challenges the notion of “low-risk
pregnancies”14 and suggests that of-
fering NIPT-based microdeletion
screening to the general pregnancy
population may be appropriate.
Although this report demonstrates the
technical ability to identify micro-
deletions, widespread implementation
will require education of care givers
and appropriate counseling of patients.
Counseling should include the perfor-
mance and scope of the testing, infor-
mation about the frequency and
phenotype of the disorders, and the
fact that testing is voluntary. We
recognize that additional validation
studies are needed to provide greater
conﬁdence in this screening test.
Overall, these genomic alterations
occur more frequently than those pres-
ently screened for, such as Down syn-
drome; many microdeletion syndromes,
including those in our study, have severe
phenotypes. As the technology im-
proves, other microdeletions and dupli-
cations should also be identiﬁable by
noninvasive testing. Although some of
these may have less severe phenotypes,
knowledge of them will allow early in-
terventions, which have been shown to
improve greatly a child’s develop-
ment.15-17 -MARCH 2015 AmeriACKNOWLEDGMENTS
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